Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay

https://doi.org/10.1016/0006-291X(90)90489-AGet rights and content

Abstract

This paper describes the analysis, by a highly sensitive and specific enzyme immunoassay (EIA), of AcSDKP, a tetrapeptide recently isolated from fetal calf bone marrow and subsequently purified and identified which substantially inhibits entry into cycle of hematopoietic pluripotent stem cells (CFU-S). This molecule has a marked protective effect in mice during anticancer chemotherapy with phase-specific drugs and plays an essential role in maintaining CFU-S out of cycle in normal mice. Using acetylcholinesterase-AcSDKP conjugate as tracer, rabbit specific antiserum and 96-well microtiter plates coated with a mouse monoclonal anti-rabbit IgG antibody, this EIA allows detection of AcSDKP at 15 fmol levels with a coefficient of variation less than 10% in the 50–500 fmol range. When combined with high-performance liquid chromatography, this assay clearly reveals the presence of this peptide in normal human white blood cells whereas in supernatant from cultured lymphocytes and in plasma the immunoreactive material is distinct from standard AcSDKP.

References (20)

  • A. Mor et al.

    Neuropeptides

    (1989)
  • L.L. McLaughlin et al.

    Biochem. Biophys. Res. Comm

    (1987)
  • E. Metreau et al.

    J. Immunol. Methods

    (1987)
  • J.L. Vaitukaitis

    Methods. Enzymol

    (1981)
  • F.M Richards et al.

    J. Mol. Biol

    (1968)
  • S. Avrameas

    Immunochemistry

    (1969)
  • S. Ruggieri et al.

    Arch. Biochem. Biophys

    (1983)
  • E Frindel et al.

    Exp. Hematol

    (1977)
  • M. Lenfant et al.
  • E. Lauret et al.

    Leukemia

    (1989)
There are more references available in the full text version of this article.

Cited by (86)

  • An analytical quality by design approach towards a simple and novel HPLC-UV method for quantification of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline

    2022, Analytical Biochemistry
    Citation Excerpt :

    Pradelles et al. first described an EIA for Ac-SDKP in 1990, using acetylcholinesterase-Ac-SDKP conjugate as the tracer, rabbit antiserum, and mouse anti-rabbit IgG antibody-coated 96-well plate. However, a limitation of this method was the lack of specificity, resulting in cross-reactivity with Ac-SDKP-like materials [12]. Junot et al. reported an improved EIA assay for the amidated analogue of the peptide, with successful quantification of the peptide analogue in the mouse plasma samples without interference from the endogenous Ac-SDKP.

  • Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice

    2012, International Immunopharmacology
    Citation Excerpt :

    In human active LN, the expression of TGF-β1 and MCP-1 mRNA in the urinary sediment was significantly elevated and correlated with SLEDAI score and histologic activity index, suggesting the importance of inflammatory infiltration and TGF-β1 expression in the progression of LN [7]. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is an endogenous tetrapeptide present in plasma and mononuclear cells [8]. Ac-SDKP is produced by cleavage of its precursor thymosin-β4 under catalyzation of prolyl oligopeptidase [9].

  • Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry

    2011, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    However, the few useful and reliable assays to screen endogenous Ac-SDKP in human plasma such as hemodialysis whom was administered ACE inhibitors have been reported. The old papers described that the enzyme immunoassay (EIA) was developed for the investigation of distribution of N-terminal thymosin β tetrapeptides [11,12]. Junot et al. reported that specific EIA was developed for sensitive and selective monitoring Ac-SDKP in mouse plasma and tissues [13].

View all citing articles on Scopus
View full text